

AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** A pharmaceutical composition including a combination of (a) at least one hyperlipidemic agent with (b) an α -glucosidase inhibitor, wherein:

the hyperlipidemic agent (a) ~~is a fibrate compound~~ fenofibrate or a salt thereof,

the α -glucosidase inhibitor (b) comprises voglibose or a salt thereof,

the proportion of the α -glucosidase inhibitor (b) is 0.01 to 10 parts by weight relative to 100 parts by weight of the hyperlipidemic agent (a), and

the pharmaceutical is

(i) a pharmaceutical composition comprising the hyperlipidemic agent (a) and the α -glucosidase inhibitor (b), or

(ii) a pharmaceutical combination including a pharmaceutical component comprising the hyperlipidemic agent (a) and a pharmaceutical component comprising the α -glucosidase inhibitor (b).

2-9. **(Cancelled)**

10. **(Currently Amended)** ~~A~~ The pharmaceutical composition according to claim 1, which includes ~~including~~ a combination of fenofibrate and voglibose, which is

(i) a pharmaceutical composition comprising the fenofibrate and the voglibose, or

(ii) a pharmaceutical combination including a pharmaceutical component comprising the fenofibrate and a pharmaceutical component comprising the voglibose.

11. **(Previously Presented)** The pharmaceutical composition according to claim 1, which is an agent for the treatment of metabolic syndrome.

12. **(Previously Presented)** The pharmaceutical composition according to claim 1, which is an agent for the treatment of diabetes.

13. **(Previously Presented)** The pharmaceutical composition according to claim 1, which is an agent for the treatment of hyperlipemia.

14. **(Cancelled)**

15. **(Previously Presented)** The pharmaceutical composition according to claim 1, which is

(i) a pharmaceutical preparation comprising (a) the hyperlipidemic agent and (b) the α -glucosidase inhibitor, or

(ii) a pharmaceutical combination including a pharmaceutical preparation comprising the hyperlipidemic agent (a) and a pharmaceutical preparation comprising the α -glucosidase inhibitor (b).

16. **(Currently Amended)** A method for preparing a pharmaceutical composition, which comprises mixing (a) at least one hyperlipidemic agent and (b) an α -glucosidase inhibitor, in a proportion of the α -glucosidase inhibitor (b) relative to the hyperlipidemic agent (a) of 0.01/100 to 10/100 (weight ratio),

wherein the hyperlipidemic agent (a) is a ~~fibrate compound~~ fenofibrate or a salt thereof, and the α -glucosidase inhibitor (b) comprises voglibose or a salt thereof.

17. **(Currently Amended)** A pharmaceutical composition reducing a side effect or dose of an α -glucosidase inhibitor, which includes a combination of (a) at least one hyperlipidemic agent and (b) an α -glucosidase inhibitor, wherein:

the hyperlipidemic agent (a) is a ~~fibrate compound~~ fenofibrate or a salt thereof,

the α -glucosidase inhibitor (b) comprises voglibose or a salt thereof,

the proportion of the α -glucosidase inhibitor (b) is 0.01 to 10 parts by weight relative to 100 parts by weight of the hyperlipidemic agent (a), and

the pharmaceutical composition is

(i) a pharmaceutical composition comprising the hyperlipidemic agent (a) and the α -glucosidase inhibitor (b), or

(ii) a pharmaceutical combination including a pharmaceutical component comprising the hyperlipidemic agent (a) and a pharmaceutical component comprising the α -glucosidase inhibitor (b).

18. **(Withdrawn)** A method for treating at least one symptom selected from the group consisting of metabolic syndrome, hyperlipemia, a symptom of diabetes, diabetes complications, a symptom of hyperglycemia after a meal in diabetics, impaired glucose tolerance (IGT), decrease of glucose tolerance, a symptom of hypertension, hyperinsulinemia, hyperammonemia, obesity or a complication thereof, fatty liver, and a symptom of hepatitis; wherein the method comprises

administering (a) at least one hyperlipidemic agent selected from the group consisting of a fibrate compound and a hydroxymethylglutaryl-CoA reductase inhibitor and (b) an α -glucosidase inhibitor to human or non-human animals to treat the symptom.

19. **(Currently Amended)** The pharmaceutical composition according to claim ~~10~~1, which is an agent for the treatment of metabolic syndrome.

20. **(Currently Amended)** The pharmaceutical composition according to claim ~~10~~1, which is an agent for the treatment of diabetes.

21. **(Currently Amended)** The pharmaceutical composition according to claim ~~10~~1, which is an agent for the treatment of hyperlipemia.

22. **(Cancelled)**